Abstract
Aim: To establish HIV-1 RNA and proviral DNA dynamics at early times after seroconvertion, to evaluate V3 quasispecies (viral diversity and proportion of X4 variants) and to assess correlations between early quasispecies composition and clinical evolution. Methods: Nineteen HIV-acutely infected patients were enrolled within 4 wks from seroconversion (T0). Nine patients remained free of therapy, 10 started HAART according to standard guidelines. HIV RNA, proviral DNA and CD4 were monitored along a 6 month follow-up. Viral quasispecies was assessed at T0 by V3 ultra-deep pyrosequencing (UDPS); prediction of co-receptor usage was performed by PSSM. Results: At T0, HIV-1 RNA and proviral DNA were positively correlated (r=0.494, p=0.032). No correlation between HIV-1 RNA and CD4 was observed. Diversity and proportion of X4 variants were positively correlated (r=0.677, p=0.001). The median proportion of X4 variants in the circulating HIV quasispecies was 0.3% (range: 0.0- 56.25%), with only 9 out of 19 patients displaying X4 variants below 0.3%. At T0, CD4 cell counts were lower in patients who started treatment (p=0.028). In addition, a significant higher diversity was observed, at this time, in patients who underwent early treatment as compared to those who remained free of therapy (p=0.028). The decline of both HIV-1 RNA and HIV-1 DNA was significantly higher in HAART treated patients as compared to the untreated group ( p<0.001 and p=0.040). Discussion: UDPS may represent a breakthrough in the study of HIV pathogenesis, providing quantitative evaluation of viral diversity and X4 frequency in viral quasispecies. Filling of proviral DNA circulating reservoirs is an early event during acute infection and HAART is able to significantly counteract this phenomenon. The observed strong correlation between viral diversity and X4 frequency is consistent with the enrichment of X4 variants along virus evolution within each infected individual.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: JAIDS Journal of Acquired Immune Deficiency Syndromes
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.